AXYS Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXYS Pharmaceuticals Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (247)	3/8/1999 11:30:00 AM
From: Tiger	Read Replies (1) of 455

Bob, The sell-off (after the correction from 8 to 6) began after the earnings and conference call as investors started worrying about the early stage of the company's drugs. I agree with you that AXPH is way too cheap at current price. IMO, AXPH is not like other early stage biotech firms. It has a solid cash position (about $2.4 per share at the end of 1998), exciting technology platforms, and management that executed and delivered (at least so far). In particular, I like the potential of their majority-owned ventures, Xyris (funded by experienced agibio venture capitalists) and PPGx (funded by the successful CRO PPDI). I have been averaging down aggressively the last two weeks and plan to continue doing so if the price goes further down. Good luck to all longs. Our days will come. Tiger

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next